(Q30577042)

English

Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomis

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 June 2017

Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomis (English)

1 reference

Europe PubMed Central

PubMed publication ID

25 June 2017

0 references

0 references

prostate cancer

1 reference

based on heuristic

inferred from title

2

object named as

Ethan Basch

1 reference

Europe PubMed Central

PubMed publication ID

25 June 2017

4

object named as

Karim Fizazi

1 reference

Europe PubMed Central

PubMed publication ID

25 June 2017

18

object named as

Howard I Scher

1 reference

Europe PubMed Central

PubMed publication ID

25 June 2017

10

object named as

Cora N Sternberg

1 reference

Europe PubMed Central

PubMed publication ID

25 June 2017

author name string

Christopher J Logothetis

1

1 reference

Europe PubMed Central

PubMed publication ID

25 June 2017

Arturo Molina

3

1 reference

Europe PubMed Central

PubMed publication ID

25 June 2017

Scott A North

5

1 reference

Europe PubMed Central

PubMed publication ID

25 June 2017

Kim N Chi

6

1 reference

Europe PubMed Central

PubMed publication ID

25 June 2017

Robert J Jones

7

1 reference

Europe PubMed Central

PubMed publication ID

25 June 2017

Oscar B Goodman

8

1 reference

Europe PubMed Central

PubMed publication ID

25 June 2017

Paul N Mainwaring

9

1 reference

Europe PubMed Central

PubMed publication ID

25 June 2017

Eleni Efstathiou

11

1 reference

Europe PubMed Central

PubMed publication ID

25 June 2017

Dennis D Gagnon

12

1 reference

Europe PubMed Central

PubMed publication ID

25 June 2017

Margaret Rothman

13

1 reference

Europe PubMed Central

PubMed publication ID

25 June 2017

Yanni Hao

14

1 reference

Europe PubMed Central

PubMed publication ID

25 June 2017

Cameron S Liu

15

1 reference

Europe PubMed Central

PubMed publication ID

25 June 2017

Thian S Kheoh

16

1 reference

Europe PubMed Central

PubMed publication ID

25 June 2017

Christopher M Haqq

17

1 reference

Europe PubMed Central

PubMed publication ID

25 June 2017

Johann S de Bono

19

1 reference

Europe PubMed Central

PubMed publication ID

25 June 2017

publication date

9 November 2012

1 reference

Europe PubMed Central

PubMed publication ID

25 June 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

25 June 2017

13

1 reference

Europe PubMed Central

PubMed publication ID

25 June 2017

12

1 reference

Europe PubMed Central

PubMed publication ID

25 June 2017

1210-1217

1 reference

Europe PubMed Central

PubMed publication ID

25 June 2017

A new therapy paradigm for prostate cancer founded on clinical observations

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970473-4

7 January 2021

based on heuristic

inferred from DOI database lookup

What is the real impact of bone pain on survival in patients with metastatic hormone-refractory prostate cancer treated with docetaxel?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970473-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Mortality following bone metastasis and skeletal-related events among men with prostate cancer: a population-based analysis of US Medicare beneficiaries, 1999-2006

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970473-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970473-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Predictive factors for skeletal complications in hormone-refractory prostate cancer patients with metastatic bone disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970473-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970473-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Bone-specific growth inhibition of prostate cancer metastasis by atrasentan

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970473-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970473-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970473-4

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970473-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Mechanisms underlying the development of androgen-independent prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970473-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Osteoblasts in prostate cancer metastasis to bone

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970473-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Molecular determinants of resistance to antiandrogen therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970473-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Abiraterone and increased survival in metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970473-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970473-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970473-4

7 January 2021

based on heuristic

inferred from DOI database lookup

The Brief Pain Inventory and its "pain at its worst in the last 24 hours" item: clinical trial endpoint considerations

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970473-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970473-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Assessing the minimally clinically significant difference: scientific considerations, challenges and solutions

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970473-4

7 January 2021

based on heuristic

inferred from DOI database lookup

When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970473-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970473-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Pain predicts overall survival in men with metastatic castration-refractory prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970473-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Improving outcomes with recent advances in chemotherapy for castrate-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970473-4

7 January 2021

based on heuristic

inferred from DOI database lookup

The clinical importance of changes in the 0 to 10 numeric rating scale for worst, least, and average pain intensity: analyses of data from clinical trials of duloxetine in pain disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970473-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970473-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970473-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: a phase III study of the European organization for research and treatment of cancer genitourinary group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970473-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(12)70473-4

1 reference

Europe PubMed Central

PubMed publication ID

25 June 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 June 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30577042&oldid=2186353114"